Welcome to our dedicated page for Gossamer Bio news (Ticker: GOSS), a resource for investors and traders seeking the latest updates and insights on Gossamer Bio stock.
Gossamer Bio, Inc. (NASDAQ: GOSS) is a San Diego-based clinical-stage biopharmaceutical company dedicated to the discovery, acquisition, development, and commercialization of novel therapeutics in the areas of immunology, inflammation, and oncology. Founded by the former executive team of Receptos, Gossamer Bio leverages a rich asset in-licensing environment with a focus on addressing high unmet medical needs.
The company's core strategy revolves around utilizing a team with a proven track record in key therapeutic areas such as immunology, inflammation, fibrosis, and oncology. Gossamer Bio's pipeline includes several promising products:
- Seralutinib: Aimed at treating pulmonary arterial hypertension (PAH) by addressing cellular overgrowth, fibrosis, and vascular remodeling.
- GB004: Focused on treating inflammatory bowel diseases such as ulcerative colitis and Crohn's disease.
- GB1275: Targeting various oncology indications with innovative treatment strategies.
- GB001: Designed for the treatment of moderate-to-severe eosinophilic asthma.
Gossamer Bio's approach combines cutting-edge science with a commitment to improving patient outcomes. The company continuously works on expanding its pipeline through strategic partnerships and collaborations, ensuring a robust portfolio of therapeutic candidates.
Recent achievements include advancements in clinical trials for Seralutinib and GB004, showcasing the company's potential to deliver impactful treatments. Gossamer Bio remains focused on executing its mission to bring differentiated therapeutic solutions to patients with significant unmet needs.
For investors and stakeholders, Gossamer Bio represents a dynamic and innovative player in the biopharmaceutical space, committed to scientific excellence and patient-centric solutions.
Gossamer Bio, Inc. (NASDAQ: GOSS) granted non-executive employees stock options under the 2023 Inducement Plan. The options allow the purchase of up to 323,000 shares at $0.755 per share, vesting over four years. This grant aims to incentivize and retain new employees in accordance with Nasdaq rules.
Gossamer Bio, Inc. (Nasdaq: GOSS) announced its first quarter 2024 financial results and business update. The company reported $396 million in cash, pro forma for a $160 million reimbursement payment and debt repayment. They are collaborating with Chiesi for seralutinib development and co-commercialization. The PROSERA Phase 3 study for PAH is ongoing, with top-line results expected in Q4 2025. A registrational Phase 3 study for PH-ILD is set to begin in mid-2025. TORREY Phase 2 PAH results were published in Lancet Respiratory Medicine, with additional data to be presented at ATS in May.
Gossamer Bio and Chiesi Group have announced a global collaboration to develop and commercialize Seralutinib for pulmonary hypertension. Gossamer will receive development reimbursement and milestones payments, leading the US commercialization activities. Chiesi obtains exclusive ex-US commercial rights with Gossamer receiving royalties on net sales. A Phase 3 trial of Seralutinib in PH-ILD is planned for mid-2025.
Gossamer Bio, Inc. announced the publication of the TORREY Phase 2 study results in the Lancet Respiratory Medicine, showcasing the positive impact of seralutinib in treating pulmonary arterial hypertension. The study demonstrated significant improvements in pulmonary vascular resistance and other key disease measures. This milestone sets the stage for the Phase 3 PROSERA Study, highlighting the potential of seralutinib to enhance the quality of life for PAH patients.
FAQ
What is the current stock price of Gossamer Bio (GOSS)?
What is the market cap of Gossamer Bio (GOSS)?
What is Gossamer Bio, Inc.?
Where is Gossamer Bio, Inc. located?
What are the main areas of focus for Gossamer Bio's therapeutic products?
Who founded Gossamer Bio, Inc.?
What is Seralutinib used for?
What conditions does GB004 target?
What is GB1275 used to treat?
What stage is Gossamer Bio at in its development?
How does Gossamer Bio expand its pipeline?
What is GB001 designed for?
